Impact of Raltegravir or Efavirenz on Cell-Associated Human Immunodeficiency Virus-1 (HIV-1) Deoxyribonucleic Acid and Systemic Inflammation in HIV-1/Tuberculosis Coinfected Adults Initiating Antiretroviral Therapy.
HIV integrase inhibitors
HIV-1 DNA
inflammation
raltegravir
tuberculosis
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
09
10
2019
accepted:
02
01
2020
entrez:
22
2
2020
pubmed:
23
2
2020
medline:
23
2
2020
Statut:
epublish
Résumé
In view of the fast viremia decline obtained with integrase inhibitors, we studied the respective effects of initiating efavirenz (EFV) or raltegravir (RAL)-based antiretroviral therapy (ART) regimens on human immunodeficiency virus (HIV)-1 deoxyribonucleic acid (DNA) levels and inflammation biomarkers in the highly inflammatory setting of advanced HIV-1 disease with tuberculosis (TB) coinfection. We followed cell-associated HIV-1 DNA, high-sensitivity C-reactive protein (hsCRP), interleukin 6 (IL-6), soluble CD14 and D-Dimer levels for 48 weeks after ART initiation in the participants to the ANRS12-180 REFLATE-TB study. This phase II open-label randomized study included ART-naive people with HIV and TB treated with rifampicin to receive RAL 400 mg twice daily (RAL400), RAL 800 mg twice daily (RAL800) or EFV 600 mg QD with tenofovir and lamivudine. In 146 participants, the median (interquartile range [IQR]) week (W)0 HIV-1 DNA level was 4.7 (IQR, 4.3-5.1) log In participants with HIV and TB, EFV, RAL400, or RAL800 effectively and equally reduced inflammation and HIV-1 DNA levels.
Sections du résumé
BACKGROUND
BACKGROUND
In view of the fast viremia decline obtained with integrase inhibitors, we studied the respective effects of initiating efavirenz (EFV) or raltegravir (RAL)-based antiretroviral therapy (ART) regimens on human immunodeficiency virus (HIV)-1 deoxyribonucleic acid (DNA) levels and inflammation biomarkers in the highly inflammatory setting of advanced HIV-1 disease with tuberculosis (TB) coinfection.
METHODS
METHODS
We followed cell-associated HIV-1 DNA, high-sensitivity C-reactive protein (hsCRP), interleukin 6 (IL-6), soluble CD14 and D-Dimer levels for 48 weeks after ART initiation in the participants to the ANRS12-180 REFLATE-TB study. This phase II open-label randomized study included ART-naive people with HIV and TB treated with rifampicin to receive RAL 400 mg twice daily (RAL400), RAL 800 mg twice daily (RAL800) or EFV 600 mg QD with tenofovir and lamivudine.
RESULTS
RESULTS
In 146 participants, the median (interquartile range [IQR]) week (W)0 HIV-1 DNA level was 4.7 (IQR, 4.3-5.1) log
CONCLUSIONS
CONCLUSIONS
In participants with HIV and TB, EFV, RAL400, or RAL800 effectively and equally reduced inflammation and HIV-1 DNA levels.
Identifiants
pubmed: 32083147
doi: 10.1093/ofid/ofz549
pii: ofz549
pmc: PMC7019658
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofz549Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
PLoS Med. 2008 Oct 21;5(10):e203
pubmed: 18942885
EBioMedicine. 2015 Apr 1;2(4):334-340
pubmed: 26114158
PLoS One. 2013 Dec 18;8(12):e83514
pubmed: 24367599
AIDS. 2010 Sep 24;24(15):2391-5
pubmed: 20683319
Nat Med. 2009 Aug;15(8):893-900
pubmed: 19543283
Antimicrob Agents Chemother. 2009 Jul;53(7):2852-6
pubmed: 19433563
J Infect Dis. 2014 Oct 15;210(8):1228-38
pubmed: 24755434
Open Forum Infect Dis. 2019 Jan 31;6(2):ofz015
pubmed: 30800697
Nat Med. 2010 Apr;16(4):460-5
pubmed: 20228817
Front Microbiol. 2011 Jan 26;2:2
pubmed: 21687401
PLoS Pathog. 2017 Apr 20;13(4):e1006285
pubmed: 28426825
J Infect Dis. 2017 Apr 15;215(8):1270-1274
pubmed: 28329310
J Antimicrob Chemother. 2015 Feb;70(2):550-4
pubmed: 25261424
Clin Infect Dis. 2015 Dec 15;61(12):1862-70
pubmed: 26270687
Clin Infect Dis. 2015 Aug 15;61(4):651-60
pubmed: 25904376
AIDS Res Ther. 2016 May 12;13:22
pubmed: 27182275
Open Forum Infect Dis. 2017 Nov 28;4(4):ofx262
pubmed: 29308409
PLoS One. 2015 Dec 04;10(12):e0144317
pubmed: 26636578
PLoS One. 2012;7(3):e31990
pubmed: 22396745
HIV Med. 2015 Aug;16(7):449-54
pubmed: 25959989
J Clin Virol. 2017 Jun;91:18-24
pubmed: 28395180
Clin Infect Dis. 2015 Oct 15;61(8):1328-35
pubmed: 26105170
J Infect Dis. 2013 Nov 1;208(9):1436-42
pubmed: 23975885
Curr Opin HIV AIDS. 2016 Mar;11(2):234-41
pubmed: 26575148
J Clin Virol. 2019 Aug;117:61-67
pubmed: 31229934
AIDS. 2011 Nov 13;25(17):2069-78
pubmed: 21860347
J Clin Microbiol. 2012 Feb;50(2):258-63
pubmed: 22135262
J Infect Dis. 2015 Aug 1;212(3):345-54
pubmed: 25583168
Clin Microbiol Rev. 2016 Oct;29(4):859-80
pubmed: 27559075
J Med Virol. 2009 Feb;81(2):217-23
pubmed: 19107966
Clin Infect Dis. 2016 Oct 1;63(7):984-990
pubmed: 27343547
Clin Infect Dis. 2014 Nov 1;59(9):1312-21
pubmed: 25073894
Lancet Infect Dis. 2014 Jun;14(6):459-67
pubmed: 24726095
AIDS. 2012 Sep 24;26(15):1885-94
pubmed: 22992577
J Infect Dis. 2017 Mar 15;215(6):911-919
pubmed: 28453847